WA
JAZZ icon

Whipplewood Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Whipplewood Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16
Closed -$1.49K – 1242
2025
Q1 		$1.49K Buy
16
+4
+33% +$522 ﹤0.01% 945
2024
Q4 		$1.48K Buy
+12
New +$1.41K ﹤0.01% 934

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Whipplewood Advisors's JAZZ Position: Q2 2025 in Review

Whipplewood Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2025, closing a stake of 16 shares — an estimated $1.49K sold.

Whipplewood Advisors first reported a position in JAZZ in Q4 2024 and held it in 2 quarters. The position peaked at $1.49K in Q1 2025. 501 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.

  • Whipplewood Advisors reported no remaining Jazz Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Whipplewood Advisors sold 16 Jazz Pharmaceuticals shares in Q2 2025, an estimated $1.49K.
  • Whipplewood Advisors first reported a position in Jazz Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Whipplewood Advisors's Jazz Pharmaceuticals position peaked at $1.49K in Q1 2025.
  • 501 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.

Based on Whipplewood Advisors's 13F filing for Q2 2025, filed 31 Jul 2025.